| Literature DB >> 23401283 |
Chad W Johnston1, Rostyslav Zvanych, Nadiya Khyzha, Nathan A Magarvey.
Abstract
EXPANDING OUR KNOWLEDGE: Natural lipocyclocarbamate natural products have provided the inspiration for the first-in-class synthetic phospholipase inhibitor darapladib, currently in phase III clinical trials for the treatment of atherosclerosis. Here, we discuss their biosynthesis by a nonribosomal peptide synthetase.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23401283 DOI: 10.1002/cbic.201200598
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164